4//SEC Filing
Jones Cecilia 4
Accession 0001439222-25-000019
CIK 0001439222other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:15 PM ET
Size
21.0 KB
Accession
0001439222-25-000019
Insider Transaction Report
Form 4
Jones Cecilia
Chief Financial Officer
Transactions
- Exercise/Conversion
Common stock
2025-03-01+5,667→ 27,510 total - Award
Restricted stock units
2025-03-01+15,910→ 15,910 total→ Common stock (15,910 underlying) - Exercise/Conversion
Restricted stock units
2025-03-01−2,000→ 2,000 total→ Common stock (2,000 underlying) - Exercise/Conversion
Restricted stock units
2025-03-01−5,667→ 11,333 total→ Common stock (5,667 underlying) - Sale
Common stock
2025-03-03$35.54/sh−594$21,111→ 21,843 total - Award
Restricted stock units
2025-03-01+12,000→ 12,000 total→ Common stock (12,000 underlying) - Award
Stock options (right to buy)
2025-03-01+43,500→ 43,500 totalExercise: $35.54Exp: 2035-03-01→ Common stock (43,500 underlying) - Exercise/Conversion
Common stock
2025-03-01+2,000→ 22,437 total - Sale
Common stock
2025-03-03$35.54/sh−1,681$59,743→ 25,829 total
Footnotes (8)
- [F1]Includes 279 shares purchased through the Company's employee stock purchase plan.
- [F2]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
- [F3]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.
- [F4]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- [F5]The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.
- [F6]This option was granted on March 1, 2025. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- [F7]The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
- [F8]The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001840056
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:15 PM ET
- Size
- 21.0 KB